An Optical Coherence Tomography-Guided, Variable Doing Regimen with Intravitreal Ranibizumab (Lucenti) for Neovacular Age-related Macular Degeneration Original Reearch Article

Purpoe To evaluate an optical coherence tomography (OCT)-guided, variable-doing regimen with intravitreal ranibizumab for the treatment of patient with neovacular age-related macular degeneration (AMD). Deign Open-label, propective, ingle-center, nonrandomized, invetigator-ponored clinical tudy. Method In thi two-year tudy, neovacular AMD patient with ubfoveal choroidal neovacularization (CNV) (n = 40) and a central retinal thickne of at leat 300 μm a meaured by OCT were enrolled to receive three conecutive monthly intravitreal injection of ranibizumab (0.5 mg). Thereafter, retreatment with ranibizumab wa performed if one of the following change wa oberved between viit: a lo of five letter in conjunction with fluid in the macula a detected by OCT, an increae in OCT central retinal thickne of at leat 100 μm, new-onet claic CNV, new macular hemorrhage, or peritent macular fluid detected by OCT at leat one month after the previou injection of ranibizumab. Reult At month 12, the mean viual acuity improved by 9.3 letter (P < .001) and the mean OCT central retinal thickne decreaed by 178 μm (P < .001). Viual acuity improved 15 or more letter in 35% of patient. Thee viual acuity and OCT outcome were achieved with an average of 5.6 injection over 12 month. After a fluid-free macula wa achieved, the mean injection-free interval wa 4.5 month before another reinjection wa neceary. Concluion Thi OCT-guided, variable-doing regimen with ranibizumab reulted in viual acuity outcome imilar to the Phae III clinical tudie, but required fewer intravitreal injection. OCT appear ueful for determining when retreatment with ranibizumab i neceary.